Pharma R&D hub BioCity appoints new CFO
pharmafile | November 3, 2015 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | BioCity, Paul Oliver
BioCity, the UK bioscience incubator, has appointed Paul Oliver as chief financial officer as it prepares to grow across its four sites in England and Scotland.
Paul Oliver joins BioCity, having previously been chief financial officer of the FTSE 250 pharma company Vectura Group where he helped oversee a major €130m international acquisition and a £52m equity placing on the London Stock Exchange.
On joining BioCity, Oliver says: “I’m excited to be joining such a unique organisation. BioCity is exemplary in the way it supports, nurtures and invests in early stage biotech companies and I look forward to helping BioCity continue the excellent progress it has made to date.”
Speaking about Paul Oliver’s appointment, BioCity CEO Glenn Crocker says: “We are delighted to welcome Paul to BioCity at this exciting period in the Company’s growth. Paul is an established and well-regarded CFO, who has gained considerable relevant experience within the UK pharmaceutical industry. His strong financial control, market knowledge and transaction experience will be a considerable asset for BioCity.”
Related Content
Scotland leading the UK in life science start-up growth, report reveals
A new report published by the life science incubator and business collective BioCity has painted …
Medicity in £1.4 million expansion in boost for life sciences
Medicity has announced that it has managed to raise the funds to refurbish an additional …
MediCity hub moves forward
Nine new businesses have signed tenancy agreements at Nottingham’s MediCity, bringing to 20 the number …